Printer Friendly

CEPHALON, INC. HIRES VICE PRESIDENT MANUFACTURING

 WEST CHESTER, Pa., Feb. 22 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) today announced the appointment of R. Edward Branson, Ph.D. to vice president manufacturing. In his new position, Dr. Branson will be responsible for operations at the company's recently acquired, 20,000 square-foot recombinant manufacturing facility in Beltsville, Md. He will also act as liaison for the manufacture of all of Cephalon's products worldwide.
 Dr. Branson, age 46, is a seasoned manufacturing executive with fourteen years of experience in all areas of biological manufacturing. Prior to joining Cephalon, he was employed by Baxter Biotech-Hyland Division as the Director of Contract Biotechnology Manufacturing where he was responsible for overseeing the planning, implementation and maintenance of manufacturing and process development methods for Baxter's recombinant Factor-VIII product. Prior to this, Dr. Branson was Vice President Manufacturing for Bio-Response, Inc. He received his doctorate from the University of North Carolina in Biochemistry and Nutrition.
 "Dr. Branson's experience in all aspects of the manufacturing process is extremely valuable to Cephalon," commented Dr. Frank Baldino, Jr., President and CEO of Cephalon. "Our recruiting a senior executive with Dr. Branson's experience to this post underscores our commitment to manufacturing and is an important milestone in our efforts to become a more integrated pharmaceutical company."
 Dr. Branson's first responsibility will be overseeing the production of Myotrophin(TM) which is currently being manufactured in Beltsville and is being developed as a potential therapeutic for the treatment of amyotrophic lateral sclerosis (ALS) and certain peripheral neuropathies. Myotrophin is currently in Phase II/III clinical trials for the treatment of ALS.
 Cephalon, Inc. discovers and develops pharmaceutical products for the treatment of neurological diseases and disorders. The company's primary focus is on neurodegenerative diseases which are characterized by the death of neurons, the specialized conducting cells of the nervous system. The company has concentrated its research programs on the prevention of neuronal death in several disorders, including ALS and peripheral neuropathy, Alzheimer's disease, head and spinal cord injury and stroke.
 -0- 2/22/93
 /CONTACT: Lyn Hyduke, assistant director of corporate communications of Cephalon, Inc., 215-344-0200, or Karen Bergman or Burns McClellan, 212-505-1919, for Cephalon, Inc./
 (CEPH)


CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU: PER

TS -- NYM006 -- 8788 02/22/93 08:32 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 22, 1993
Words:374
Previous Article:LUMEX REPORTS STRONG INCREASE IN FOURTH QUARTER AND FULL YEAR EARNINGS
Next Article:KENNECOTT TO BUY CORDERO COAL MINE FROM SUN COMPANY, ADDING TO ITS POWDER RIVER BASIN HOLDINGS
Topics:


Related Articles
CEPHALON AND SCHERING-PLOUGH CONTINUE RESEARCH COLLABORATION
CEPHALON, INC. PRESENTS PROMISING DATA ON SMALL MOLECULE NEUROTROPHIC FACTORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CEPHALON, INC. ACQUIRES U.S. MANUFACTURING FACILITY
CEPHALON NAMES BRUCE PEACOCK COO AND DIRECTOR
Cephalon Announces Management Promotions.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters